FindTrial
Sign In

Effectiveness of the screening and brief intervention for hazardous and harmful cannabis use among patients on opioid agonist treatment (OAT)coming at the Drug Deaddiction and Treatment Center at PGIMER, Chandigarh in the year 20-21

Efficacy of screening and brief intervention for hazardous and harmful cannabis use among patients on opioid agonist treatment (OAT):A randomized control trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/09/028072
Enrollment
150
Registered
2020-09-28
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F12- Cannabis related disorders Health Condition 2: F11- Opioid related disorders

Interventions

Intervention1: Screening and brief intervention for harmful and hazardous cannabis use: Study will be conducted in 2 phase with initial screening of patients using ASSIST questionairre followed by 15

Sponsors

Department Of Psychiatry and Drug De addiction Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients on OAT, taking cannabis, receiving OAT for at least 3 months, adherent with OAT for at least one month, scoring between 4 to 26 in Cannabis specific ASSIST score, who provide written informed consent and who are capable to read Hindi and English

Exclusion criteria

Exclusion criteria: Unwilling to participate in the study, ASSIST Score less than 4 or more than 26 for cannabis, BI by existing treatment program in the past 3 months

Design outcomes

Primary

MeasureTime frame
Primary outcome measure of the study will be reduction in mean ASSIST score after 90 (Ã?± 14) days of brief intervention and general adviceTimepoint: 90 (Ã?± 14) days—

Secondary

MeasureTime frame
Secondary outcome will be change in frequency and amount of cannabis and opioid use, and adherence with buprenorphine-naloxone based agonist therapy after 90 (Ã?±14) days of brief intervention and general adviceTimepoint: 90 (Ã?± 14) days—

Countries

India

Contacts

Public ContactDr Abhishek Ghosh

PGIMER

ghoshabhishek12@gmail.com9815890436

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026